Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2019.18939
Abstract: This systematic review and meta-analysis evaluates whether progression-free survival is a validated surrogate end point for overall survival in patients with advanced ovarian cancer. read more here.
Keywords: end point; free survival; point overall; surrogate end ... See more keywords
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.49591
Abstract: Key Points Question Is tumor mutational burden (TMB) associated with outcomes among patients with locally advanced unresectable non–small cell lung cancer (NSCLC) treated with definitive chemoradiation and consolidative durvalumab? Findings In this cohort study of… read more here.
Keywords: locally advanced; free survival; durvalumab; progression free ... See more keywords
Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Medicine"
DOI: 10.1002/cam4.1217
Abstract: Overall survival (OS) is the gold‐standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity… read more here.
Keywords: end; end point; overall survival; progression free ... See more keywords
Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5067
Abstract: In patients with advanced melanoma, immune‐checkpoint inhibitors (ICIs) represent the mainstay for first line treatment. Recently, relatlimab+nivolumab was proposed as a new combination therapy. This review was aimed at summarizing the current data of effectiveness… read more here.
Keywords: advanced melanoma; free survival; checkpoint inhibitors; immune checkpoint ... See more keywords
The validity of progression‐free survival 2 as a surrogate trial end point for overall survival
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34085
Abstract: Overall survival (OS) is the gold‐standard end point for oncology trials. However, the availability of multiple therapeutic options after progression and crossover to receive investigational agents confound and delay OS data maturation. Progression‐free survival 2… read more here.
Keywords: free survival; end point; progression free; survival ... See more keywords
A proper statistical inference framework to compare clinical trial and real‐world progression‐free survival data
Sign Up to like & getrecommendations! Published in 2022 at "Statistics in Medicine"
DOI: 10.1002/sim.9590
Abstract: The past decade has witnessed an increasing trend in utilizing external control data in clinical trials, especially in the form of synthetic control arms (SCA) derived from real‐world or historical trial data. Including such data… read more here.
Keywords: free survival; progression free; framework; trial ... See more keywords
PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study
Sign Up to like & getrecommendations! Published in 2017 at "World Journal of Urology"
DOI: 10.1007/s00345-017-2138-x
Abstract: PurposeTo evaluate the association between prostate-specific antigen (PSA) response and progression-free and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel.MethodsMen with mCRPC receiving cabazitaxel (25 mg/m2, every 3 weeks) plus oral prednis(ol)one… read more here.
Keywords: free survival; psa response; progression free; survival ... See more keywords
Computed tomography-based radiomics signature as a pretreatment predictor of progression-free survival in locally advanced hypopharyngeal carcinoma with a different response to induction chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "European Archives of Oto-Rhino-Laryngology"
DOI: 10.1007/s00405-022-07306-w
Abstract: To establish and validate a radiomics signature for stratifying the risk of progression-free survival (PFS) in patients with locally advanced hypopharyngeal carcinoma (LAHC) undergoing induction chemotherapy (IC). We extracted radiomics features from baseline contrast-enhanced computed… read more here.
Keywords: risk; free survival; signature; progression free ... See more keywords
Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival
Sign Up to like & getrecommendations! Published in 2018 at "European Spine Journal"
DOI: 10.1007/s00586-018-5764-0
Abstract: Background and aimsThe aim of this systematic review is to describe the epidemiology of chordoma and to provide a clear overview of clinical prognostic factors predicting progression-free and overall survival.MethodsFour databases of medical literature were… read more here.
Keywords: factors predicting; prognostic factors; epidemiology; predicting progression ... See more keywords
Diabetes mellitus contributes to carbamazepine resistance in patient with trigeminal neuralgia
Sign Up to like & getrecommendations! Published in 2020 at "Neurosurgical Review"
DOI: 10.1007/s10143-020-01304-4
Abstract: Objective To determine whether diabetes mellitus (DM) contributes to the drug resistance of carbamazepine (CBZ), we investigated the correlation between the blood glucose status and the CBZ resistance condition in patients with trigeminal neuralgia (TN).… read more here.
Keywords: cbz resistance; free survival; diabetes mellitus; resistance ... See more keywords
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "PharmacoEconomics"
DOI: 10.1007/s40273-018-0625-6
Abstract: BackgroundThe recently completed ALEX trial demonstrated that alectinib improved progression-free survival, and delayed time to central nervous system progression compared with crizotinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. However, the long-term clinical… read more here.
Keywords: alectinib crizotinib; anaplastic lymphoma; cost; alectinib ... See more keywords